Hinge Therapeutics is an early-stage biopharmaceutical company focused on developing small-molecule therapeutics against traditionally undruggable/challenging targets for unmet medical needs.

The Hinge Drug Discovery Platform, our proprietary technology, has generated several novel inactivators against targets which are traditionally targeted only by large molecules such as antibody and siRNA.

Current areas of interest include:

• Hemophilia and other bleeding disorders
• Solid tumors (immune oncology approach targeting tumor microenvironment)
• Cardiovascular Diseases 
• CNS (including Alzheimer’s)
• Rare Disease
• Anti-aging

Our proprietary Hinge Drug Discovery Platform which includes Hinge Database, Hinge-Blast and Hinge Library has generated several small molecules which modulate protein conformation of targets and act as inhibitors which are traditionally targeted only by large molecules such as antibody and siRNA.